EXAGEN CEO share sale covers RSU tax withholding

EXAGEN INC. reported an insider transaction by President and CEO John Aballi involving a mandatory share sale to cover taxes.

Rhea-AI Filing Summary

EXAGEN INC. reported an insider transaction by President and CEO John Aballi involving a mandatory share sale to cover taxes. On this Form 4, Aballi sold 11,430 shares of common stock at $3.61 per share, with the sale directed by the company solely to satisfy tax withholding obligations tied to vesting and settlement of restricted stock units. The filing states this was not a discretionary trade by Aballi. Following the transaction, he directly held 702,997 common shares, and there is an additional indirect holding of 40,401 shares reported as owned by his spouse.

Insider Trade Summary

Net Seller: 11,430 shares

Net Sell 2 txns

Insider ABALLI JOHN

Role President and CEO

Sold 11,430 shs ($41K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,430	$3.61	$41K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 702,997 shares (Direct); Common Stock — 40,401 shares (Indirect, by Spouse)

Footnotes (1)

1. F1. The sale reported on this Form 4 represents shares sold by the Reporting Person, at the direction of the Issuer, to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated solely by the Issuer and does not represent a discretionary transaction by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EXAGEN INC. (XGN) report for John Aballi?

EXAGEN INC. reported that CEO John Aballi had 11,430 common shares sold at $3.61 each. The transaction covered tax withholding arising from restricted stock units vesting and was directed by the company, not a discretionary open‑market trade by Aballi.

Was the EXAGEN (XGN) CEO’s Form 4 sale a discretionary stock sale?

No, the Form 4 explains the sale was mandated by EXAGEN to cover tax withholding from vesting restricted stock units. It explicitly states the sale does not represent a discretionary transaction by CEO John Aballi in the open market.

How many EXAGEN (XGN) shares were sold in the tax‑withholding transaction?

The filing reports 11,430 shares of EXAGEN common stock were sold. The sale price was $3.61 per share, and the purpose was to satisfy tax withholding obligations on the vesting and settlement of restricted stock units granted to the CEO.

How many EXAGEN (XGN) shares does CEO John Aballi hold after this Form 4?

After the reported transaction, John Aballi directly holds 702,997 EXAGEN common shares. The Form 4 also lists an additional 40,401 shares as an indirect holding, reported as owned by his spouse, separate from his direct ownership position.

What does the footnote in EXAGEN (XGN) CEO’s Form 4 explain about the sale?

The footnote explains the sale was executed at EXAGEN’s direction solely to cover tax withholding obligations. It clarifies that the transaction is related to restricted stock unit vesting and is not a discretionary decision by CEO John Aballi to sell shares.

How does the EXAGEN (XGN) Form 4 classify the CEO’s ownership type?

The Form 4 shows 702,997 EXAGEN shares as directly owned by CEO John Aballi. It also reports 40,401 shares as indirectly owned, categorized as held “by Spouse,” distinguishing personal holdings from those attributed to a related individual.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 07:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABALLI JOHN

(Last) (First) (Middle)

C/O EXAGEN INC.

1261 LIBERTY WAY

(Street)

VISTA CA 92081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		S(1)		11,430	D	$3.61	702,997	D
Common Stock								40,401	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person, at the direction of the Issuer, to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated solely by the Issuer and does not represent a discretionary transaction by the Reporting Person.

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.